1. Blauvelt A. Pityriasis rosea.

In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell
DJ, Wolff K, editors. Dermatology in general medicine fitzpatrick’s. 8th ed. New York: The
McGraw-Hill Companies; 2012. p. 458-63.
2. James WD, Berger TG, Elston DM, Neuhaus IM. Andrews’ diseases of the skin clinical
dermatology. 12th ed. Philadelphia: Elsevier; 2016. p. 199-201
3. Sterling JC. Viral infection. In: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer
D, editors. Rook’s textbook of dermatology. 8th ed. Massachusetts: Blackwell publishing;
2016. p. 33.78-81.
4. Nikolic M. Pityriasis Rosea. In: European Handbook of Dermatological Treatments. 3rd
ed. Berlin: Springer-Verlag Berlin Heidelberg; 2015. p. 749-52
5. Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis rosea: a comprehensive
classification. Dermatology. 2016; 232(4): 431-7
(https://www.karger.com/Article/Abstract/445375 diakses pada 19 Juni 2018).
6. Konsil Kedokteran Indonesia. Standar kompetensi dokter indonesia. Jakarta: KKI; 2012.
hal. 54.
7. Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H. The Role of Cytokines,
Hemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea. Hindawi
Publishing Corporation: Mediators Inflamm. 2015;115(10):1-6
(https://www.hindawi.com/journals/mi/2015/438963/abs/ diakses pada 22 Juni 2018).
8. Ganguly S. A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy of Oral
Acyclovir in the Treatment of Pityriasis rosea. Journal of clinical and diagnostic research:
JCDR. 2014 May;8(5):YC01 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080052/
diakses pada 22 Juni 2018).
9. Weller, R.B. Hamish JA, Hunter, Margaret WM. Clinical Dermatology. 5th ed. John Wiley
& Sons, Ltd; 2015. p.68-69.
10. Urbina F, Das A, Sudy E. Clinical variants of pityriasis rosea. World journal of clinical
cases. 2017 Jun 16;5(6):203.
11. Neoh, C. Y., et al. "Characterization of the Inflammatory Cell Infiltrate in Herald Patches
and Fully Developed Eruptions of Pityriasis Rosea." Clinical and experimental
dermatology 35.3 (2010): 300-304.
12. Kartowigno S. Pitiriasis rosea. In: Sepuluh besar kelompok penyakit kulit. Palembang:
Unsri Press; 2012. p. 93-5.
13. Chuh AA. Diagnostic criteria for pityriasis rosea: A prospective case control study for
assessment of validity. J Eur Acad Dermatol Venereol. 2003;17:101–3.
14. Zawar V, Chuh A. Applicability of proposed diagnostic criteria of pityriasis rosea: results
of a prospective case-control study in india. Indian J Dermatol. 2013;58(6):439-42.
15. Djuanda A, Triestianawati W. Pitiriasis Rosea. In: Menaldi SL, editor. Ilmu penyakit kulit
dan kelamin. 7th ed. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2015. p. 225-7.
16. Wolff, K., Johnson, R.A., Suurmond, D. Fitzpatrick Color Atlas and Synopsis of Clinical
Dermatology Edition 5th.The McGraw-Hill Companies. United States. 2005
17. Amatya, A., E. A. Rajouria, and D. K. Karn. "Comparative study of effectiveness of oral
acyclovir with oral erythromycin in the treatment of pityriasis rosea." Kathmandu
University Medical Journal 10.1 (2012): 48-52.
18. Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is
associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005;
124:1234-40.